FDA studying physical attributes of generic drugs; Drug-device partnership to treat brain cancer debuts;

> The FDA is studying how the color, shape or size of a generic drug affects patient adherence, as it seeks to improve patient compliance with labeling and doctors' orders. More

> DNAtrix will use its Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, its candidate for treating a form of aggressive brain cancer known as glioblastoma. More

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.